Editas Medicine to Participate in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

Chardan Virtual 4th Annual Genetic Medicines ConferenceFireside ChatDate: Monday, October 5, 2020Time: 10:30 a.m. ET

The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor ContactMark Mullikin(617) 401-9083[email protected]

Media ContactCristi Barnett(617) 401-0113[email protected]

You May Also Be Interested In

• Proficient Auto Logistics Announces Pricing of $75 Million Convertible Bond Offering
• Optimal Transit Unveils Second Configuration of the Kraaken™ Data Center: A Ship That Can Power 32,000 Homes, Produce Clean Water for 150,000 People, and Host 60 MW of AI Compute – With No Fuel an
• Verizon announces a $25,000 reward program to protect communities from network vandalism